Skip to main content
NCBI home page
The BMJ logoLink to The BMJ
. 1995 Aug 5;311(7001):363–366. doi: 10.1136/bmj.311.7001.363

Double blind trial of repeated treatment with transdermal nicotine for relapsed smokers.

S G Gourlay 1, A Forbes 1, T Marriner 1, D Pethica 1, J J McNeil 1
PMCID: PMC2550432  PMID: 7640544

Abstract

OBJECTIVE--To assess the efficacy and safety of a repeat course of treatment with transdermal nicotine for cessation of smoking in a brief intervention setting. STUDY DESIGN--Randomised, double blind, placebo controlled trial with follow up for 26 weeks. SUBJECTS--629 smokers who had unsuccessfully attempted to stop smoking by using active transdermal nicotine and brief behavioural counselling. Smokers were motivated to quit smoking for a second time and smoked > or = 15 cigarettes a day. INTERVENTIONS--Twelve weeks' treatment with active transdermal nicotine patches or placebo and brief counselling at monthly visits. MAIN OUTCOME MEASURE--Sustained smoking cessation for the 28 days before the visit at week 12 verified by expired carbon monoxide concentrations. RESULTS--At 12 weeks 21/315 (6.7%) subjects allocated to active treatment had stopped smoking compared with 6/314 (1.9%) allocated to placebo (absolute difference 4.7%; 95% confidence interval 1.6% to 7.9%; P = 0.003). At 26 weeks the rates were 20/315 (6.4%) and 8/314 (2.6%) (3.8%; 0.6% to 7.0%; P = 0.021). Difficulty in sleeping was reported by 43/179 (24.0%) on active treatment and 19/143 (13.3%) on placebo (P = 0.015). Severe reactions at the site of application were rare (6/322; 1.9%). CONCLUSIONS--Repeated treatment with transdermal nicotine together with brief counselling can improve the low success rates of smoking cessation in recently relapsed, moderate to heavy smokers. Questions remain about whether more intensive interventions or higher doses of nicotine could be more effective. The likelihood of severe reactions at the site of application with repeated treatment is low.

Full text

PDF
363

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Fiore M. C., Novotny T. E., Pierce J. P., Giovino G. A., Hatziandreu E. J., Newcomb P. A., Surawicz T. S., Davis R. M. Methods used to quit smoking in the United States. Do cessation programs help? JAMA. 1990 May 23;263(20):2760–2765. [PubMed] [Google Scholar]
  2. Fiore M. C., Smith S. S., Jorenby D. E., Baker T. B. The effectiveness of the nicotine patch for smoking cessation. A meta-analysis. JAMA. 1994 Jun 22;271(24):1940–1947. [PubMed] [Google Scholar]
  3. Foulds J., Stapleton J., Feyerabend C., Vesey C., Jarvis M., Russell M. A. Effect of transdermal nicotine patches on cigarette smoking: a double blind crossover study. Psychopharmacology (Berl) 1992;106(3):421–427. doi: 10.1007/BF02245429. [DOI] [PubMed] [Google Scholar]
  4. Gourlay S. G., Forbes A., Marriner T., Pethica D., McNeil J. J. Prospective study of factors predicting outcome of transdermal nicotine treatment in smoking cessation. BMJ. 1994 Oct 1;309(6958):842–846. doi: 10.1136/bmj.309.6958.842. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Gourlay S. G., McNeil J. J. Antismoking products. Med J Aust. 1990 Dec 3;153(11-12):699–707. doi: 10.5694/j.1326-5377.1990.tb126327.x. [DOI] [PubMed] [Google Scholar]
  6. Haxby D., Sinclair A., Eiff M. P., McQueen M. H., Toffler W. L. Characteristics and perceptions of nicotine patch users. J Fam Pract. 1994 May;38(5):459–464. [PubMed] [Google Scholar]
  7. Levin E. D., Westman E. C., Stein R. M., Carnahan E., Sanchez M., Herman S., Behm F. M., Rose J. E. Nicotine skin patch treatment increases abstinence, decreases withdrawal symptoms, and attenuates rewarding effects of smoking. J Clin Psychopharmacol. 1994 Feb;14(1):41–49. [PubMed] [Google Scholar]
  8. Murray R. P., Connett J. E., Lauger G. G., Voelker H. T. Error in smoking measures: effects of intervention on relations of cotinine and carbon monoxide to self-reported smoking. The Lung Health Study Research Group. Am J Public Health. 1993 Sep;83(9):1251–1257. doi: 10.2105/ajph.83.9.1251. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Pierce J. P., Gilpin E., Farkas A. J. Nicotine patch use in the general population: results from the 1993 California Tobacco Survey. J Natl Cancer Inst. 1995 Jan 18;87(2):87–93. doi: 10.1093/jnci/87.2.87. [DOI] [PubMed] [Google Scholar]
  10. Stapleton J. A., Russell M. A., Feyerabend C., Wiseman S. M., Gustavsson G., Sawe U., Wiseman D. Dose effects and predictors of outcome in a randomized trial of transdermal nicotine patches in general practice. Addiction. 1995 Jan;90(1):31–42. doi: 10.1046/j.1360-0443.1995.901316.x. [DOI] [PubMed] [Google Scholar]
  11. Tønnesen P., Nørregaard J., Säwe U., Simonsen K. Recycling with nicotine patches in smoking cessation. Addiction. 1993 Apr;88(4):533–539. doi: 10.1111/j.1360-0443.1993.tb02060.x. [DOI] [PubMed] [Google Scholar]
  12. United States Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 1991 [5 November 1990]. Digest Public Gen Bills. 1990;101(Pt 2)(1):263–264. [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES